Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: A positive association with combined CYP/GST genotypes

Clinical and Experimental Medicine

Volumn 8, Issue 2, 2008, Pages 65-71

  Torresan, C ^a   Oliveira, M M C ^a   Torrezan, G T ^a   De Oliveira, S F V ^a   Abuazar C S ^a   Losi Guembarovski, R ^a   Lima, R S ^b   Urban, C A ^b   Cavalli, I J ^a   Ribeiro, E M S F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

Author keywords

Breast cancer; Genetic polymorphisms; Oestrogen; Xenobiotic metabolising genes

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANK SUM TEST;

ADULT; AGED; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; ESTROGENS; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 47349132331     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-008-0159-x     Document Type: Article

References (41)

1. INCA/MS, Instituto Nacional de Câncer do Ministério da Saúde (2007) http://www.inca.org.br. Accessed July 2007
2. Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Nat Cancer Inst Monographs 27:67-73
3. Nebert DW, Mckinnon RA, Puga A (1996) Human-drug metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280
4. Han W, Kang D, Park, IA et al (2004) Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin Cancer Res 10:124-130
5. Kawajiri K, Nakach IK, Imai K et al (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P-450IA1 gene. FEBS Lett 263:131-133
6. Taioli E, Trachman J, Chen X et al (1995) A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757-3758
7. Taioli E, Bradlow HL, Garbers SV et al (1999) Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 23:232-237
8. Garte S, Gaspari L, Alexandrie AK et al (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239-1248
9. Crocitto LE, Feigelson HS, Yu MC et al (1997) A polymorphism in intron 6 of the CYP17 gene. Clin Genet 52:68-69
10. Carey AH, Waterworth D, Patel K et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Mol Genet 3:1873-1876
11. Kristensen VN, Haraldsen EK, Anderson KB et al (1999) CYP17 and breast cancer risk: the polymorphism in the 5 flanking area of the gene does not influence binding to Sp-1. Cancer Res 59:2825-2828
12. Hong CC, Thompson HJ, Jiang C et al (2004) Association between the T27C polymorphism in the cytochrome P450c17α gene (CYP17) and risk factors for breast cancer. Breast Cancer Res Treatment 88:217-230
13. Ambrosone CB, Moysich KB, Furberg H et al (2003) CYP17 genetic polymorphism, breast cancer and breast cancer risk factors. Breast Cancer Res 5:45-51
14. Stuven T, Griese EU, Kroemer HK et al (1996) Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reaction. Pharmacogenetics 6:417-421
15. Ladona MG, Abildúa RE, Ladero JM et al (1996) CYP2D6 genotypes in Spanish women with breast cancer. Cancer Letters 99:23-28
16. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
17. Egan KM, Cai Q, Shu X et al (2004) Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai breast cancer study and meta-analysis. Cancer Epidemiol Biomark Prev 13:197-204
18. Millikan R, Pittman G, Tse C et al (2000) Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomark Prev 9:567-573
19. Parl FF (2005) Glutathione S-transferase genotypes and cancer risk. Cancer Lett 221:123-129
20. Forrester LM, Hayes JD, Millis R et al (1990) Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 11:2163-2170
21. Board PG, Coggan M, Johnston et al (1990) Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Therap 48:357-369
22. Mitrunen K, Jourenkova N, Kataja V et al (2001) Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomark Prev 10:229-236
23. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extraction DNA from human nucleated cell. Nucleic Acid Res 16:1215
24. Carstensen U, Alexandrie AK, Högstedt B et al (1993) B-and T-lymphocyte micronulei in chimney sweeps with respect to genetic polymorphism for CYP1A1 and GST1 (class Mu). Mut Res 289:187-195
25. McKean-Cowdin R, Feigelson HS, Pike MC et al (2001) Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 61:848-849
26. Sobit RC, Al-Badran AI, Sharma SK et al (2005) Genetics polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India. Cancer Genet Cytogenet 156:68-73
27. Abdel-Rahman SZ, El-Zein RA, Anwar WA et al (1996) A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 107:229-233
28. Harries LW, Stubbins MJ, Forman D et al (1997) Identification of genetic polymorphisms at glutathione S-transferases Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641-644
29. Miller MP (1997) RXC: a program for the analysis of contingency tables. Department of Biological Sciences, Northern Arizona University. Free program distributed by the authors over the internet from the RxC Home Page at http://herb.bio.nau.edu/miller/rxc.htm
30. Park SK, Kang D, Noh DY et al (2003) Reproductive factors, glutathione S-transferase M1 and T1 genetic polymorphism and breast cancer risk. Breast Cancer Res Treat 78:89-96
31. Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Human Reprod Update 11:545-560
32. Van Der Hel OL, Bueno-De-Mesquita HB, Van Gils CH et al (2005) Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk. Cancer Causes Control 16:675-681
33. Amorim LMF, Rossini A, Mendonça G et al (2002) CYP1A1, GSTM1 ad GSTT1 polymorphisms and breast cancer risk in Brazilian woman. Cancer Lett 181:179-186.
34. Huang CS, Shen CY, Chang KJ et al (1999) Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer 80:1838-1843
35. Bergman-Jungestrom M, Gentile M, Lundin AC and the SouthEast Breast Cancer Group (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350-353
36. Charrier J, Maugard CM, Le Mevel B, Bignon YJ (1999) Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer 79:346-353
37. Park SK, Yoo KY, Lee SJ et al (2000) Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 10:301-309
38. Roodi N, Dupont WD, Moore JH, Parl FF (2004) Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. Cancer Res 64:1233-1236
39. Matheson MC, Stevenson T, Akbarzadeh S, Propert DN (2002) GSTT1 null genotype increases risk of premenopausal breast cancer. Cancer Lett 181:73-79
40. Hunter DJ, Spielgeman D, Adami HO et al (1997) Non-dietary factors as risk factors for breast cancer and as effect modifiers of the association of fat intake and risk of breast cancer. Cancer Causes Control 8:49-56
41. Collaborative group of hormonal factors in breast cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727